# Clinical Trials Data ERBB2 - Document 26

# Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

## Clinical Trial: https://clinicaltrials.gov/study/NCT00939523

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients with nonfunctioning adenomas who have undergone at least one prior surgical resection and have demonstrated recurrence on MRI\n\* Patients with prolactinomas who are resistant to dopamine agonist therapy\n\* Patients with malignant pituitary tumors\n\* Patients with visual field deficits and/or compression of the optic chiasm must be stable for at least 6 months\n\nExclusion Criteria:\n\n\* Patients with compromised visual fields and/or compression of the optic chiasm on MRI that has not been stable for last 6 months.\n\* Patients that have reduced left ventricular ejection fraction less than 50%\n\* Patients with moderate to severe hepatic impairment\n\* Patients that are pregnant or lactating\n\* Patients under the age of 18\n\* Active hepatitis\n\* Known previous HIV Positive\n\* Concurrent cancers\n\* Life expectancy less than one year",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
This clinical trial focuses on pituitary tumors. The eligibility criteria does \*\*not\*\* mention anything about ERBB2 gene mutations. Therefore, having an ERBB2 mutation is neither explicitly included nor excluded.  
  
A patient with an ERBB2 mutation \*could\* potentially be eligible if they \*also\* met the other inclusion criteria (e.g., having a nonfunctioning adenoma with recurrence, a prolactinoma resistant to therapy, or a malignant pituitary tumor) and did \*not\* meet any of the exclusion criteria.  
  
The presence of the ERBB2 mutation alone doesn't qualify or disqualify them. More information would be needed about the patient's specific pituitary tumor situation.